HomeInsightsStock Comparison

Astrazeneca Pharma India Ltd vs Emcure Pharmaceuticals Ltd Stock Comparison

Astrazeneca Pharma India Ltd vs Emcure Pharmaceuticals Ltd Stock Comparison

Last Updated on: Apr 25, 2025

Key Highlights

  • The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8640 as of 25 Apr 11:21.
  • The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Emcure Pharmaceuticals Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Astrazeneca Pharma India Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Emcure Pharmaceuticals Ltd for the Dec '24 is ₹ 1959 crore as compare to the Sep '24 revenue of ₹ 2037 crore. This represent the decline of -3.84%.
  • The ebitda of Astrazeneca Pharma India Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Emcure Pharmaceuticals Ltd for the Dec '24 is ₹ 358.5 crore as compare to the Sep '24 ebitda of ₹ 416.53 crore. This represent the decline of -13.93%.
  • The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 140.97 crore to ₹ 156.09 crore over 7 quarters. This represents a CAGR of 5.99% .
  • The Dividend Payout of Astrazeneca Pharma India Ltd changed from 3.46 % on March 2020 to 37.15 % on March 2024 . This represents a CAGR of 60.76% over 5 yearsThe Dividend Payout of Emcure Pharmaceuticals Ltd changed from 25.8 % on March 2020 to 22.53 % on March 2024 . This represents a CAGR of -2.67% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Astrazeneca Pharma India Ltd

  • AstraZeneca Pharma India (APIL) was incorporated on July 11, 1979.
  • The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
  • The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
  • Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Emcure Pharmaceuticals Ltd

  • Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
  • Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
  • They are a research and development driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled to reach target markets across over 70 countries, with a strong presence in India, Europe and Canada.

Astrazeneca Pharma India Ltd News Hub

News

AstraZeneca Pharma gets CDSCO nod to import and distribute TAGRISSO (Osimertinib)

The newly approved indication allows Osimertinib to be used in combination with pemetrexed...

Read more

05 Apr 2025 14:43

News

Astrazeneca Pharma gains after receiving approval from CDSO to import Durvalumab solution.

Through this approval, Durvalumab in combination with Tremelimumab is indicated for the tr...

Read more

03 Mar 2025 14:43

News

Astrazeneca Pharma gains after Q3 PAT soars to Rs 55 cr

Revenue from operations jumped 44% to Rs 440.29 crore in Q3 FY25 as compared with Rs 305.7...

Read more

12 Feb 2025 11:47

News

Astrazeneca Pharma India to hold board meeting

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 1...

Read more

21 Jan 2025 10:45

News

Volumes spurt at Astrazeneca Pharma India Ltd counter

Happiest Minds Technologies Ltd, Campus Activewear Ltd, Cera Sanitaryware Ltd, ITI Ltd are...

Read more

30 Dec 2024 14:30

News

AstraZeneca gets CDSCO nod to import cancer drug, Lynparza

This approval establishes the use of Olaparib in combination with Durvalumab as a maintena...

Read more

26 Nov 2024 14:49

Emcure Pharmaceuticals Ltd News Hub

News

Emcure Pharma's pune facility receives VAI status from USFDA

The company received the Establishment Inspection Report (EIR) from the USFDA following an...

Read more

21 Apr 2025 11:09

News

Emcure subsidiary Tillomed Laboratories to acquire UK based Manx Healthcare and its subsidiaries

Tillomed Laboratories, a subsidiary of Emcure Pharmaceuticals, has entered into an Asset P...

Read more

04 Apr 2025 12:28

News

Emcure Pharma's European arm acquires Manx Healthcare for '19.7 million

The APA has also been inked with the subsidiaries of Manx, viz. Manx Pharma and Manx Gener...

Read more

04 Apr 2025 14:05

News

Emcutix Biopharmaceuticals inks in-licensing agreement with WiQo

Emcutix Biopharmaceuticals, a wholly owned subsidiary of Emcure Pharmaceuticals, announced...

Read more

02 Apr 2025 10:35

News

Emcure Pharmaceuticals forays into daily supplements space

Emcure Pharmaceuticals announced its entry into the daily supplements space with the expan...

Read more

10 Mar 2025 19:33

News

Emcure Pharma's Maharashtra facility gets 2 USFDA observations

According to an exchange filing, the inspection was conducted at the company's Active Phar...

Read more

26 Feb 2025 13:23

BlinkX Score for Emcure Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Astrazeneca Pharma India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Astrazeneca Pharma India Ltd and Emcure Pharmaceuticals Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Emcure Pharmaceuticals Ltd?

Market cap of Astrazeneca Pharma India Ltd is 22,404 Cr while Market cap of Emcure Pharmaceuticals Ltd is 20,381 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Emcure Pharmaceuticals Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Emcure Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Emcure Pharmaceuticals Ltd?

As of April 25, 2025, the Astrazeneca Pharma India Ltd stock price is INR ₹8961.95. On the other hand, Emcure Pharmaceuticals Ltd stock price is INR ₹1075.65.

How do dividend payouts of Astrazeneca Pharma India Ltd and Emcure Pharmaceuticals Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Emcure Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions